止带方联合保妇康栓治疗慢性宫颈炎合并高危型HPV感染临床研究  

Clinical Study on Zhidai Prescription Combined with Baofukang Suppository for Chronic Cervicitis and High-risk HPV Infection

作　　者：陈伶俐 方亚云 陈帮武 CHEN Lingli;FANG Yayun;CHEN Bangwu

机构地区：[1]象山县计划生育宣传指导站妇产科,浙江象山315700 [2]浙江大学附属产科医院宁海分院产科,浙江宁波315600

出　　处：《新中医》2019年第1期149-152,共4页New Chinese Medicine

摘　　要：目的:观察止带方联合保妇康栓治疗慢性宫颈炎合并高危型人乳头瘤病毒(HPV)感染的临床疗效。方法:以176例慢性宫颈炎合并高危型HPV感染患者为研究对象,按照随机数字表法分为对照组和研究组各88例,对照组给予保妇康栓治疗,研究组给予止带方联合保妇康栓治疗,记录治疗期间药物不良反应的发生情况,检测患者治疗前后血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6 (IL-6)和白细胞介素-8 (IL-8)的水平,评价2组的疗效,记录治疗结束后随访12月内患者的宫颈炎症复发情况。结果:治疗结束后,研究组总有效率95.46%,高于对照组的85.23%,差异有统计学意义(P <0.05)。研究组高危型HPV转阴率84.09%,对照组高危型HPV转阴率63.64%,2组比较,差异有统计学意义(P <0.01)。2组血清TNF-α、IL-6和IL-8水平均较治疗前降低(P <0.01),研究组血清各炎症因子水平均低于对照组(P <0.01)。随访12月内,研究组宫颈炎复发率8.33%,对照组宫颈炎复发率20.00%,2组比较,差异有统计学意义(P <0.05)。2组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论:与单用保妇康栓治疗比较,止带方联合保妇康栓可更为有效地降低慢性宫颈炎合并高危型HPV感染患者的宫颈炎症反应程度,改善临床症状,促进高危型HPV清除,预防宫颈炎复发,提高疗效,且安全性较高,值得在临床推广使用。Objective:To observe the clinical effect of Zhidai prescription combined with Baofukang suppository for chronic cervicitis and high-risk human papillomavirus(HPV)infection.Methods:Selected 176 cases of patients with chronic cervicitis and high-risk HPV infection as study subjects,and divided them into the control group and the study group according to random number table method,88 cases in each group.The control group was given Baofukang suppository for treatment,while the study group was given Zhidai prescription combined with Baofukang suppository.Recorded the adverse reactions during the treatment,detected changes in levels of tumor necrosis factor-α(TNF-α),interleukins-6(IL-6)and interleukins-8(IL-8)in serum before and after treatment,evaluated the curative effect in the two groups and followed up the recurrence of cervicitis of patients for twelve months after treatment.Results:After treatment,the total effective rate was95.46%in the study group,higher than that of 85.23%in the control group,the difference being significant(P<0.05).The negative conversion rate of HPV was 84.09%in the study group and 63.64%in the control group,the difference being significant(P<0.01).Levels of TNF-α,IL-6 and IL-8 in serum in the two groups were decreased when compared with those before treatment(P<0.01),and the levels of inflammatory factors in serum in the study group were lower than those in the control group(P<0.01).After twelve months of follow-up,the recurrence rate of cervicitis was 8.33%in the study group and 20.00%in the control group,the difference being significant(P<0.05).No significant difference was found in the comparison of the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with the treatment of Zhidai prescription,the therapy of Zhidai prescription combined with Baofukang suppository can more effectively reduce the inflammatory response of cervicitis of patients with chronic cervicitis and HPV infection,improve the clinicalsymptoms,promote the clearance of high-risk HPV,pr

关 键 词：慢性宫颈炎 人乳头瘤病毒(HPV) 高危型HPV感染 止带方 保妇康栓 炎症因子 

分 类 号：R711.32[医药卫生—妇产科学]